Vident Investment Advisory’s Vertex Pharmaceuticals VRTX Stock Holding History

Vident Investment Advisory’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-53,106	Closed	-$18.7M	–	1051
2023 Q2	$18.7M	Sell	53,106 -4,471	-8%	-$1.51M	0.64%	21
2023 Q1	$18.1M	Buy	57,577 +4,325	+8%	+$1.3M	0.59%	21
2022 Q4	$15.4M	Buy	53,252 +21,209	+66%	+$6.46M	0.58%	29
2022 Q3	$8.97M	Sell	32,043 -4,234	-12%	-$1.22M	0.29%	79
2022 Q2	$10.2M	Sell	36,277 -5,177	-12%	-$1.39M	0.31%	71
2022 Q1	$10.8M	Buy	41,454 +11,330	+38%	+$2.69M	0.28%	75
2021 Q4	$6.62M	Buy	30,124 +9,645	+47%	+$1.88M	0.17%	133
2021 Q3	$3.71M	Buy	20,479 +17,423	+570%	+$3.4M	0.11%	182
2021 Q2	$616K	Sell	3,056 -700	-19%	-$146K	0.02%	785
2021 Q1	$808K	Buy	3,756 +1,552	+70%	+$341K	0.03%	674
2020 Q4	$521K	Buy	2,204 +173	+9%	+$39.7K	0.02%	701
2020 Q3	$553K	Sell	2,031 -1,191	-37%	-$329K	0.03%	639
2020 Q2	$935K	Buy	+3,222	New	+$874K	0.05%	500
2018 Q2	–	Sell	-1,380	Closed	-$219K	–	976
2018 Q1	$219K	Buy	+1,380	New	+$225K	0.01%	842
2015 Q3	–	Sell	-50	Closed	-$6K	–	1157
2015 Q2	$6K	Buy	+50	New	+$6.3K	﹤0.01%	1003

Other funds holding VRTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vident Investment Advisory's VRTX Position: Q3 2023 in Review

Vident Investment Advisory sold out of Vertex Pharmaceuticals (VRTX) in Q3 2023, closing a stake of 53,106 shares — an estimated $18.7M sold.

Vident Investment Advisory first reported a position in VRTX in Q2 2015 and held it in 15 quarters. The position peaked at $18.7M in Q2 2023. 1,277 funds tracked by Wall St. Rank hold VRTX as of Q3 2023.

Vident Investment Advisory reported no remaining Vertex Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Vident Investment Advisory sold 53,106 Vertex Pharmaceuticals shares in Q3 2023, an estimated $18.7M.
Vident Investment Advisory first reported a position in Vertex Pharmaceuticals in Q2 2015 and held it in 15 quarters.
Vident Investment Advisory's Vertex Pharmaceuticals position peaked at $18.7M in Q2 2023.
1,277 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2023.

Based on Vident Investment Advisory's 13F filing for Q3 2023.